Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Share-based Compensation (2020 - 2023)

Candel Therapeutics' Share-based Compensation history spans 4 years, with the latest figure at $939000.0 for Q4 2023.

  • For Q4 2023, Share-based Compensation rose 48.11% year-over-year to $939000.0; the TTM value through Dec 2023 reached $3.1 million, up 33.98%, while the annual FY2024 figure was $5.3 million, 71.85% up from the prior year.
  • Share-based Compensation for Q4 2023 was $939000.0 at Candel Therapeutics, up from $686000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.9 million in Q3 2021 and bottomed at -$446000.0 in Q4 2021.
  • The 4-year median for Share-based Compensation is $709500.0 (2023), against an average of $728357.1.
  • The largest YoY upside for Share-based Compensation was 2200.0% in 2021 against a maximum downside of 125.44% in 2021.
  • A 4-year view of Share-based Compensation shows it stood at $1.8 million in 2020, then crashed by 125.44% to -$446000.0 in 2021, then surged by 242.15% to $634000.0 in 2022, then surged by 48.11% to $939000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Share-based Compensation are $939000.0 (Q4 2023), $686000.0 (Q3 2023), and $733000.0 (Q2 2023).